The trial reached both its Principal endpoints, with semaglutide 2.4 mg demonstrating statistically considerable and excellent improvements in liver fibrosis without having worsening of steatohepatitis, along with resolution of steatohepatitis with no worsening of liver fibrosis in individuals with MASH compared to placebo.1These highlights never i